mg-1

MG 1 is a potent alpha-1 adrenergic receptor antagonist.

Anti-mouse ICOSL/CD275 antibody, targeting ICOSL/CD275.

MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis.

AMG-1694, a potent disruptor of the glucokinase–glucokinase regulatory protein (GK-GKRP) complex, operates by promoting the dissociation of this complex, thereby indirectly enhancing GK enzymatic activity with an IC50 of 7 nM. It effectively normalizes blood glucose levels in various rodent diabetes models [1] and lowers blood glucose specifically in diabetic animals without affecting normoglycemic ones. Additionally, AMG-1694 reverses the GKRP-induced inhibition of GK activity and facilitates GK translocation.

hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.

hSMG-1 inhibitor 11j is a pyrimidine derivative. hSMG-1 inhibitor 11j is a potent and selective inhibitor of hSMG-1, IC50 = 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer.

KMG-104 is a selective Mg2+ fluorescent probe for dynamic observation of Mg2+ in the cytoplasm of living cells.

MG-115 (Z-LL-Nva-CHO) is a potent and reversible inhibitor of proteasome , with K i s of 21 nM and 35 nM for 20S and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis [1] [2] [3].

MG-101 (Calpain inhibitor I) is a cell-permeable and potent inhibitor of cysteine proteases including calpains and lysosomal cathepsins.

MG-1102 is a first-in-class dual binder of monomeric tau and pre-miRNA-146a, exhibiting specific inhibition of miRNA146a with IC 50 values of 0.21 mM for double-labeled pre-miRNA146a and 0.36 mM for mono-labeled pre-miRNA146a. It interacts with tau monomers with a K d of 3.21 mM as determined by surface plasmon resonance (SPR), positioning it as a potential multi-target-directed ligand (MTDL) for Alzheimer's disease (AD) [1].

(R)-MG-132 (Z-Leu-D-leu-leu-al) is the enantiomer of MG-132.

MMG-11 inhibits both TLR2/1 and TLR2/6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2/1 and 5.7 μM for Pam2CSK4-induced hTLR2/6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.

KMG-1068 (Compound 4a), a molecular glue, acts as a GSPT1/2 degrader. By binding to the IMiD binding site on CRBN, KMG-1068 efficiently induces CRBN-dependent degradation of GSPT1/2 and facilitates the formation of a ternary complex with GSPT1/2. KMG-1068 holds potential for use in cancer research.

MMG-1, a monoalkylglycerol, acts as a C-type lectin receptor agonist and stabilizes lipid membranes. It functions as an immune adjuvant in liposomes and is useful in formulating lipid nanoparticles for drug delivery.

AMG-126737 is an effective human lung mast cell trypsin inhibitor with potential therapeutic effect in lung diseases.

MMG-11 quarterhydrate is a potent and selective antagonist of human TLR2, inhibiting both TLR2/1 and TLR2/6 signaling with low cytotoxicity. The IC50 values for Pam3CSK4-induced hTLR2/1 and Pam2CSK4-induced hTLR2/6 responses are 1.7 μM and 5.7 μM, respectively [1].

AMG-1 is a specific CRAC channel inhibitor. AMG-1 blocks the function of effector T cells, but not regulatory T cells in vitro and it attenuates the progression and severity of EAE in vivo.

AMG-131 besylate is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.

AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.

MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. It activates NF-κB signaling in T cells and enhances NK cell-mediated tumor-killing activity in a PVR-dependent manner. By blocking TIGIT, MG-1131 increases IFN-γ secretion. This compound is applicable for research in antitumor immunity. Recommended isotype control: HumanIgG1kappa, Isotype Control.

AMG-167 is a monoclonal antibody targeting sclerostin, utilized in cancer research. Additionally, AMG-167 can be applied in studies related to osteoporosis.

AMG-172 Antibody is an antibody targeting CD70. It can be used for the synthesis of ADCMG-172.

AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 is applicable for research in relapsed/refractory (R/R) small cell lung cancer (SCLC).

MG-132 negative control serves as the negative control for MG-132. MG-132 is a potent and reversible inhibitor of the proteasome (proteasome).